SCHEMBL10187752

SCHEMBL10187752

O=C(O)NCC(=O)c1ccc(Br)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.55
HAO1 Q9UJM8 1/20 0.53
HDAC1 Q13547 3/20 0.52
HDAC8 Q9BY41 3/20 0.52
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC10 Q969S8 1/20 0.52
HDAC11 Q96DB2 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
HDAC9 Q9UKV0 1/20 0.52
HDAC5 Q9UQL6 1/20 0.52
ALDH1A1 P00352 4/20 0.51
MAPT P10636 2/20 0.51
GAA P10253 1/20 0.51
OGG1 O15527 1/20 0.48
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
KMT2A Q03164 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11558787 0.85 HAO1 (0.54) GSK3BHAO1HDAC1HDAC8HDAC3
SCHEMBL7963547 0.84 GSK3B (0.55) GSK3BHAO1HDAC1HDAC8HDAC3
SCHEMBL7963549 0.82 GSK3B (0.53) GSK3BHAO1HDAC1HDAC8HDAC3
SCHEMBL3323642 0.82 GSK3B (0.53) GSK3BHAO1HDAC1HDAC8HDAC3
SCHEMBL9837130 0.82 PTPN1 (0.52) ALDH1A1MAPTGAACES2KMT2A
SCHEMBL11216066 0.81 MEN1 (0.62) GSK3BALDH1A1MAPTGAACES1
SCHEMBL15973607 0.80 MAPT (0.58) ALDH1A1MAPTCES2CES1KMT2A
SCHEMBL14830961 0.80 ERCC5 (0.58) GSK3BALDH1A1MAPTCES2CES1
Methane SCHEMBL9835792 0.80 NPC1 (0.50) ALDH1A1MAPTGAAKMT2AHPGD
SCHEMBL5640455 0.79 GSK3B (0.50) GSK3BHAO1HDAC1HDAC8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348386-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-11-02 US disclosed
EP-4234552-A2 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-3426244-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-06-07 EP disclosed
US-11535593-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-12-27 US disclosed
US-20220017464-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2022-01-20 US disclosed
US-11014882-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-05-25 US disclosed
US-20190071400-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-03-07 US disclosed
EP-3426244-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics Inc. (US) 2019-01-16 EP disclosed
WO-2017156179-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-09-14 WO disclosed
WO-2012123298-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 WO disclosed
US-20120230951-A1 ANTIVIRAL COMPOUNDS ALAM MUZAFFAR (US) 2012-09-13 US disclosed
CN-102596936-A Antiviral compounds GILEAD SCIENCES INC 2012-07-18 CN disclosed
EP-2473056-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2012-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348386-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD GSK3B 288/4885HAO1 410/4885HDAC1 533/4885
US-11535593-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD GSK3B 288/4885HAO1 410/4885HDAC1 533/4885
US-11014882-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD GSK3B 288/4885HAO1 410/4885HDAC1 533/4885
US-20120230951-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS GSK3B 575/4885HAO1 4259/4885HDAC1 1057/4885
US-20190071400-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD GSK3B 288/4885HAO1 410/4885HDAC1 533/4885
US-20220017464-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD GSK3B 288/4885HAO1 410/4885HDAC1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.